@article{TLCR15648,
author = {Mari Mino- Kenudson},
title = {Immunohistochemistry for predictive biomarkers in non-small cell lung cancer},
journal = {Translational Lung Cancer Research},
volume = {6},
number = {5},
year = {2017},
keywords = {},
abstract = {In the era of targeted therapy, predictive biomarker testing has become increasingly important for non-small cell lung cancer. Of multiple predictive biomarker testing methods, immunohistochemistry (IHC) is widely available and technically less challenging, can provide clinically meaningful results with a rapid turn-around-time and is more cost efficient than molecular platforms. In fact, several IHC assays for predictive biomarkers have already been implemented in routine pathology practice. In this review, we will discuss: (I) the details of anaplastic lymphoma kinase (ALK) and proto-oncogene tyrosine-protein kinase ROS (ROS1) IHC assays including the performance of multiple antibody clones, pros and cons of IHC platforms and various scoring systems to design an optimal algorithm for predictive biomarker testing; (II) issues associated with programmed death-ligand 1 (PD-L1) IHC assays; (III) appropriate pre-analytical tissue handling and selection of optimal tissue samples for predictive biomarker IHC.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/15648}
}